Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.53 |
| ▸ | MAOA | P21397 | 5/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20468698 | 1.00 | SLC6A4 (0.53) | SLC6A4MAOAMAOBPTGS2HTR2A | |
| SCHEMBL835786 | 0.81 | SLC6A4 (0.53) | SLC6A4MAOAHTR2AHTR2B | |
| SCHEMBL13175896 | 0.76 | SLC6A4 (0.53) | SLC6A4MAOAMAOBPTGS2 | |
| SCHEMBL17688579 | 0.76 | SLC6A4 (0.50) | SLC6A4MAOAMAOBPTGS2HTR2A | |
| SCHEMBL17688578 | 0.76 | SLC6A4 (0.50) | SLC6A4MAOAMAOBPTGS2HTR2A | |
| SCHEMBL28700561 | 0.75 | SLC6A4 (0.53) | SLC6A4MAOAMAOBPTGS2HTR2A | |
| Hydrochloric Acid SCHEMBL17710304 | 0.74 | SLC6A4 (0.49) | SLC6A4MAOAMAOBPTGS2HTR2A | |
| SCHEMBL28556620 | 0.73 | SLC6A4 (0.47) | SLC6A4MAOAPTGS2 | |
| SCHEMBL19705371 | 0.72 | SLC6A4 (0.50) | SLC6A4MAOAMAOBPTGS2HTR2A | |
| SCHEMBL1104208 | 0.72 | SLC6A4 (0.50) | SLC6A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222902-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | SLC6A4 4687/4885MAOA 4051/4885MAOB 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.